Thyroid cancer: Cabozantinib effective in selected patients
Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.163 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancer
Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.161 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.157Cholangiocarcinoma, the second most common form of liver cancer after hepatocellular carcinoma, is a heterogeneous disease entity with a near-universal poor prognosis. Our understanding of the epidemiology and biology of cholangiocarcinoma is increasing, and importantly, potentially actionable molecular and immunological targets for novel therapies are increasingly being identified. Herein, the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma are reviewed. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Sumera Rizvi Shahid A. Khan Christopher L. Hallemeier Robin K. Kelley Gregory J. Gores Source Type: research
Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
Nature Reviews Clinical Oncology, Published online: 4 October 2017; doi:10.1038/nrclinonc.2017.156On 30th August 2017, tisagenlecleucel became the first chimeric antigen receptor (CAR)-T-cell therapy to be approved by the FDA. This approval has important implications for health-care systems because the use of this promising treatment presents considerable logistical, toxicological, and financial challenges. Moreover, the high price tag of US$475,000 is questionable, considering the major role of US taxpayers in covering the development, delivery, and supportive-care costs of this treatment. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 4, 2017 Category: Cancer & Oncology Authors: Vinay Prasad Source Type: research
Patient-reported outcomes in cancer care — hearing the patient voice at greater volume
Nature Reviews Clinical Oncology, Published online: 4 October 2017; doi:10.1038/nrclinonc.2017.153In the past decade, the importance of patient-reported outcomes (PROs) as a key measure of the quality of care delivered to patients with cancer has been acknowledged. PROs were used in the context of research studies, but growing evidence indicates that the incorporation of electronic PRO (ePRO) assessments into standard health-care settings can improve the quality of care delivered to patients with cancer. The authors of this Review discuss aspects related to PROs such as measurements, implementation challenges, and outcome ...
Source: Nature Clinical Practice Oncology - October 4, 2017 Category: Cancer & Oncology Authors: Thomas W. LeBlanc Amy P. Abernethy Source Type: research
